Literature DB >> 8018546

Rapid detection, cloning and molecular cytogenetic characterisation of sequences from an MRP-encoding amplicon by chromosome microdissection.

M E Ray1, X Y Guan, M L Slovak, J M Trent, P S Meltzer.   

Abstract

Chromosome microdissection was utilised for the analysis of cytogenetic markers of gene amplification [homogeneously staining regions (hsrs) and double minutes (dmins)] in two doxorubicin-resistant cell lines, fibrosarcoma HT1080/DR4 and small-cell lung cancer H69AR. Microdissection products from the hsr(7)(p12p15) of HT1080/DR4 were amplified and used for fluorescent in situ hybridisation (micro-FISH) analysis of drug-sensitive HT1080, resistant HT1080/DR4 and normal lymphocytes. The results demonstrated that the hsr contains a domain of DNA amplification of complex origin including sequences derived from 16p11.2-16p13.1, 2q11.2, 7q32-7q34 and 10q22. The amplification was confirmed by converting the micro-dissected probe into a microclone library for probing HT1080 and HT1080/DR4 Southerns. A micro-FISH probe from normal band region 16p11-16p13 further demonstrated amplification of 16p sequences in both HT1080/DR4 and H69AR. During the course of this analysis, Cole et al. (1992) (Science, 258, 1650-1653) published the amplification of the MRP gene in H69AR cells, which maps to chromosome 16p13.1. Our results corroborate the finding of MRP amplification in these doxorubicin-resistant cell lines, but, importantly, they provide information on the composition of the complex amplicon contributions from four different chromosomes. This study demonstrates the potential utility of chromosome microdissection for the rapid recovery of sequences from amplified regions in drug-resistant cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018546      PMCID: PMC2033297          DOI: 10.1038/bjc.1994.254

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  A genomic scanning method for higher organisms using restriction sites as landmarks.

Authors:  I Hatada; Y Hayashizaki; S Hirotsune; H Komatsubara; T Mukai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  Methods for chromosome banding of human and experimental tumors in vitro.

Authors:  J M Trent; F H Thompson
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

3.  Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.

Authors:  M L Slovak; M Coccia; P S Meltzer; J M Trent
Journal:  Anticancer Res       Date:  1991 Jan-Feb       Impact factor: 2.480

4.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

Authors:  J R Riordan; K Deuchars; N Kartner; N Alon; J Trent; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

5.  Cytogenetic alterations associated with the acquisition of doxorubicin resistance: possible significance of chromosome 7 alterations.

Authors:  M L Slovak; G A Hoeltge; J M Trent
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein.

Authors:  T McGrath; M S Center
Journal:  Biochem Biophys Res Commun       Date:  1987-06-30       Impact factor: 3.575

7.  Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

Authors:  W T Beck; M C Cirtain; M K Danks; R L Felsted; A R Safa; J S Wolverton; D P Suttle; J M Trent
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein.

Authors:  K Ueda; M M Cornwell; M M Gottesman; I Pastan; I B Roninson; V Ling; J R Riordan
Journal:  Biochem Biophys Res Commun       Date:  1986-12-30       Impact factor: 3.575

9.  Rapid generation of region-specific genomic clones by chromosome microdissection: isolation of DNA from a region frequently deleted in malignant melanoma.

Authors:  X Y Guan; P S Meltzer; J Cao; J M Trent
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

10.  Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.

Authors:  M L Slovak; G A Hoeltge; W S Dalton; J M Trent
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.